{
    "organizations": [],
    "uuid": "6d70a08a82fff42a6bb275284419ee865810443e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biogen-samsung-bioepis-to-settle-w/brief-biogen-samsung-bioepis-to-settle-with-abbvie-over-humira-biosimilar-idUSFWN1RI0F2",
    "ord_in_thread": 0,
    "title": "BRIEF-Biogen, Samsung Bioepis To Settle With AbbVie Over Humira Biosimilar",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 5 (Reuters) - Biogen Inc:\n* BIOGEN AND SAMSUNG BIOEPIS AGREE TO SETTLEMENT WITH ABBVIE ALLOWING COMMERCIALIZATION OF IMRALDIâ„¢ (ADALIMUMAB BIOSIMILAR) IN EUROPE\n* BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCTOBER 16, 2018\n* PRECISE TERMS OF AGREEMENT WITH ABBVIE ARE CONFIDENTIAL * UNDER TERMS OF AGREEMENT, ABBVIE WILL GRANT PATENT LICENSES FOR USE AND SALE OF IMRALDI IN EUROPE\n* COUNTRY BASIS * UNDER TERMS OF AGREEMENT, BIOGEN AND SAMSUNG BIOEPIS WILL MAKE ROYALTY PAYMENTS TO ABBVIE\n* COMPANIES HAVE AGREED TO DISMISS ALL PENDING PATENT LITIGATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-05T21:29:00.000+03:00",
    "crawled": "2018-04-06T21:59:16.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "biogen",
        "inc",
        "biogen",
        "samsung",
        "bioepis",
        "agree",
        "settlement",
        "abbvie",
        "allowing",
        "commercialization",
        "adalimumab",
        "biosimilar",
        "europe",
        "biogen",
        "expects",
        "launch",
        "imraldi",
        "europe",
        "october",
        "precise",
        "term",
        "agreement",
        "abbvie",
        "confidential",
        "term",
        "agreement",
        "abbvie",
        "grant",
        "patent",
        "license",
        "use",
        "sale",
        "imraldi",
        "europe",
        "country",
        "basis",
        "term",
        "agreement",
        "biogen",
        "samsung",
        "bioepis",
        "make",
        "royalty",
        "payment",
        "abbvie",
        "company",
        "agreed",
        "dismiss",
        "pending",
        "patent",
        "litigation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}